A combined phase I/II single site study to determine the safety and efficacy of photodynamic therapy (PDT) utilizing 5-aminolevulinic acid (5-ALA) and PDT in the treatment of premalignant oral and/or oropharynx lesions.

Trial Profile

A combined phase I/II single site study to determine the safety and efficacy of photodynamic therapy (PDT) utilizing 5-aminolevulinic acid (5-ALA) and PDT in the treatment of premalignant oral and/or oropharynx lesions.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2012

At a glance

  • Drugs Aminolevulinic acid (Primary)
  • Indications Orofacial cancer; Oropharyngeal cancer; Oropharyngeal dysplasia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Jan 2012 Actual end date (1 Jan 2012 ) added as reported by ClinicalTrials.gov.
    • 18 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Aug 2011 Planned end date changed from 1 Feb 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top